Avenue Therapeutics | IPO Presentation Deck | 30 slides

Avenue Therapeutics · 2022-10
arc beats above · slides in the middle · loops below · scroll → 1 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 1
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

5
coverage by narrative range · generated from this deck JSON

Slide inventory

30
every slide · same image gating as the playbook
01
Slide 1
front_matter
02
front_matter
03
establish_context
04
The slide features a high-quality illustration of neurons, emphasizing the CNS focus of the company.summarize
05
The slide uses a simple additive equation visual to represent the growth of the company's CNS portfolio.compare_peers
06
The slide uses a Gantt-style visualization to track drug development progress.plan_implementation
07
The slide uses a numbered process flow to indicate strategic priorities.plan_implementation
08
establish_context
Open slide detailBeat · Solution
09
Includes a scientific diagram of the GABAa receptor complex.establish_context
Open slide detailBeat · Solution
10
The table uses checkmarks to indicate the strength of effect for different GABA-A subtypes (alpha 1, 2, 3, 5).compare_peers
Open slide detailBeat · Solution
11
diagnose_problem
Open slide detailBeat · ProblemLoop · Cost Of Inaction
12
diagnose_problem
Open slide detailBeat · ProblemLoop · Cost Of Inaction
13
Uses a Venn-like containment diagram to show sub-segments of a larger market.size_opportunity
Open slide detailBeat · Market SizeLoop · Cost Of Inaction
14
The slide uses a hexagonal layout to present five key product attributes.establish_context
Open slide detailBeat · Market SizeLoop · Cost Of Inaction
15
The slide notes that BAER-101 was previously known as AZD7325.summarize
Open slide detailBeat · Product
16
The slide highlights the therapeutic window of BAER-101 by showing efficacy in the punished model without significant impairment in the un-punished model.analyze_data
Open slide detailBeat · Product
17
Includes a comparison to Cerevel's darigabat and lorazepam.summarize
18
The chart shows BAER-101 regimens consistently resulting in lower sleepiness rates than Lorazepam.analyze_data
19
Includes a medical warning regarding photosensitivity.present_solution
20
The slide uses a comparison table to frame BAER-101's selectivity profile as a competitive advantage.compare_peers
21
The slide uses a numbered process flow to outline corporate priorities.plan_implementation
22
The slide uses a hub-and-spoke style diagram to illustrate the dual mechanism.establish_context
23
The slide uses bar charts to demonstrate statistical significance (p < 0.001) of the drug over placebo in two different pain models.analyze_data
24
summarize
25
The slide uses a numbered process flow to delineate strategic priorities.plan_implementation
26
The slide uses a hexagonal layout to present selection criteria.state_demand
27
transition
28
introduce_nominees
Open slide detailBeat · Team
29
establish_context
Open slide detailBeat · Team
30
summarize